Expression of Melan-A in Depigmented Skin of Vitiligo Patients
暂无分享,去创建一个
[1] B. Eberlein,et al. Therapeutic management of vitiligo , 2018, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.
[2] Y. Hasija,et al. Exploring vitiligo susceptibility and management: a brief review , 2018, Biomedical Dermatology.
[3] B. Selvan,et al. Pattern of Repigmentation in the Treatment of Vitiligo Vulgaris with NBUVB Therapy , 2018 .
[4] A. Bishnoi,et al. Clinical and Molecular Aspects of Vitiligo Treatments , 2018, International journal of molecular sciences.
[5] N. Elbuluk,et al. Advances in Vitiligo: An Update on Medical and Surgical Treatments. , 2017, The Journal of clinical and aesthetic dermatology.
[6] M. A. E. Kholy. IMMUNOHISTOCHEMICAL EXPRESSION OF MELAN A AND ITS RELATION TO EXPRESSION OF CXCR3 IN VITILIGO LESIONS , 2016 .
[7] A. Kubanov,et al. Immunohistochemical analysis of melanocyte content in different zones of vitiligo lesions using the Melan-A marker. , 2016, Acta dermatovenerologica Alpina, Pannonica, et Adriatica.
[8] Liliane Machado do Nascimento,et al. Vitiligo - Part 1 , 2014, Anais brasileiros de dermatologia.
[9] D. Parsad. A New Era of Vitiligo Research and Treatment , 2013, Journal of cutaneous and aesthetic surgery.
[10] Takashi Hashimoto,et al. Disease Severity Indexes and Treatment Evaluation Criteria in Vitiligo , 2011, Dermatology research and practice.
[11] K. Sharquie,et al. Inflammatory Changes in Vitiligo: Stage I and II Depigmentation , 2004, The American Journal of dermatopathology.
[12] D. Gawkrodger,et al. Autoantibodies in vitiligo patients are not directed to the melanocyte differentiation antigen MelanA/MART1 , 2002, Clinical and experimental immunology.
[13] A. Abdel-rahman,et al. Evaluation of the Role of Apoptosis in Vitiligo: Immunohistochemical Expression of P53, Bcl-2 and MART-1 Antigens , 2002 .
[14] J. Weening,et al. Autoimmune Melanocyte Destruction in Vitiligo , 2001, Laboratory Investigation.